334 related articles for article (PubMed ID: 35115572)
21. The CXCL Family Contributes to Immunosuppressive Microenvironment in Gliomas and Assists in Gliomas Chemotherapy.
Wang Z; Liu Y; Mo Y; Zhang H; Dai Z; Zhang X; Ye W; Cao H; Liu Z; Cheng Q
Front Immunol; 2021; 12():731751. PubMed ID: 34603309
[TBL] [Abstract][Full Text] [Related]
22. Recurrence- and Malignant Progression-Associated Biomarkers in Low-Grade Gliomas and Their Roles in Immunotherapy.
Teng C; Zhu Y; Li Y; Dai L; Pan Z; Wanggou S; Li X
Front Immunol; 2022; 13():899710. PubMed ID: 35677036
[TBL] [Abstract][Full Text] [Related]
23. A Comprehensive Prognostic and Immunological Analysis of a Six-Gene Signature Associated With Glycolysis and Immune Response in Uveal Melanoma.
Liu J; Lu J; Li W
Front Immunol; 2021; 12():738068. PubMed ID: 34630418
[TBL] [Abstract][Full Text] [Related]
24. Systematically characterize the clinical and biological significances of 1p19q genes in 1p/19q non-codeletion glioma.
Chai RC; Zhang KN; Chang YZ; Wu F; Liu YQ; Zhao Z; Wang KY; Chang YH; Jiang T; Wang YZ
Carcinogenesis; 2019 Oct; 40(10):1229-1239. PubMed ID: 31157866
[TBL] [Abstract][Full Text] [Related]
25. Radiogenomics of lower-grade gliomas: a radiomic signature as a biological surrogate for survival prediction.
Qian Z; Li Y; Sun Z; Fan X; Xu K; Wang K; Li S; Zhang Z; Jiang T; Liu X; Wang Y
Aging (Albany NY); 2018 Oct; 10(10):2884-2899. PubMed ID: 30362964
[TBL] [Abstract][Full Text] [Related]
26. Investigation of Genetic Determinants of Glioma Immune Phenotype by Integrative Immunogenomic Scale Analysis.
Zhao B; Wang Y; Wang Y; Dai C; Wang Y; Ma W
Front Immunol; 2021; 12():557994. PubMed ID: 34220791
[TBL] [Abstract][Full Text] [Related]
27. Identification and validation of a 21-mRNA prognostic signature in diffuse lower-grade gliomas.
Song LR; Weng JC; Huo XL; Wang L; Li H; Li D; Wu Z; Zhang JT
J Neurooncol; 2020 Jan; 146(1):207-217. PubMed ID: 31853837
[TBL] [Abstract][Full Text] [Related]
28. Identification of three tumor antigens and immune subtypes for mRNA vaccine development in diffuse glioma.
Zhou Q; Yan X; Zhu H; Xin Z; Zhao J; Shen W; Yin W; Guo Y; Xu H; Zhao M; Liu W; Jiang X; Ren C
Theranostics; 2021; 11(20):9775-9790. PubMed ID: 34815785
[No Abstract] [Full Text] [Related]
29. Identification of an Inflammatory Response-Related Gene Signature to Predict Survival and Immune Status in Glioma Patients.
Yan Z; Gao Y; Yu J; Shen Z; Bu X
J Immunol Res; 2022; 2022():8972730. PubMed ID: 35647198
[TBL] [Abstract][Full Text] [Related]
30. Bioinformatic Profiling Identifies a Fatty Acid Metabolism-Related Gene Risk Signature for Malignancy, Prognosis, and Immune Phenotype of Glioma.
Qi Y; Chen D; Lu Q; Yao Y; Ji C
Dis Markers; 2019; 2019():3917040. PubMed ID: 31885736
[TBL] [Abstract][Full Text] [Related]
31. Construction of a novel mRNA-signature prediction model for prognosis of bladder cancer based on a statistical analysis.
Li J; Cao J; Li P; Yao Z; Deng R; Ying L; Tian J
BMC Cancer; 2021 Jul; 21(1):858. PubMed ID: 34315402
[TBL] [Abstract][Full Text] [Related]
32. Comprehensive analysis of TAMs marker genes in glioma for predicting prognosis and immunotherapy response.
Zhao Z; Wang Z; Wu Y; Liao D; Zhao B
Mol Immunol; 2022 Apr; 144():78-95. PubMed ID: 35203024
[TBL] [Abstract][Full Text] [Related]
33. Identification of hub genes related to prognosis in glioma.
Zhang D; Zhao J; Han C; Liu X; Liu J; Yang H
Biosci Rep; 2020 May; 40(5):. PubMed ID: 32406502
[TBL] [Abstract][Full Text] [Related]
34. Integrative Analysis of Inflammatory Response-Related Gene for Predicting Prognosis and Immunotherapy in Glioma.
Zhao Z; Zheng B; Zheng J; Zhang Y; Jiang C; Nie C; Jiang X; Yao D; Zhao H
J Mol Neurosci; 2023 Aug; 73(7-8):608-627. PubMed ID: 37488455
[TBL] [Abstract][Full Text] [Related]
35. Identification and validation of a novel eight mutant-derived long non-coding RNAs signature as a prognostic biomarker for genome instability in low-grade glioma.
Maimaiti A; Wang X; Pei Y; Nuermaimaiti N; Tuersunniyazi A; Abula Y; Feng Z; Jiang L; Shi X; Kasimu M
Aging (Albany NY); 2021 Jun; 13(11):15164-15192. PubMed ID: 34081618
[TBL] [Abstract][Full Text] [Related]
36. Ferroptosis-related gene signature predicts prognosis and immunotherapy in glioma.
Wan RJ; Peng W; Xia QX; Zhou HH; Mao XY
CNS Neurosci Ther; 2021 Aug; 27(8):973-986. PubMed ID: 33969928
[TBL] [Abstract][Full Text] [Related]
37. Novel roles of VAT1 expression in the immunosuppressive action of diffuse gliomas.
Yang P; Wang K; Zhang C; Wang Z; Liu Q; Wang J; Jiang T; Shan X
Cancer Immunol Immunother; 2021 Sep; 70(9):2589-2600. PubMed ID: 33576871
[TBL] [Abstract][Full Text] [Related]
38. Comprehensive profiling identifies a novel signature with robust predictive value and reveals the potential drug resistance mechanism in glioma.
Zeng F; Wang K; Liu X; Zhao Z
Cell Commun Signal; 2020 Jan; 18(1):2. PubMed ID: 31907037
[TBL] [Abstract][Full Text] [Related]
39. Mitochondrial RNA modification-based signature to predict prognosis of lower grade glioma: a multi-omics exploration and verification study.
Zhou X; Ling Y; Cui J; Wang X; Long N; Teng W; Liu J; Xiang X; Yang H; Chu L
Sci Rep; 2024 Jun; 14(1):12602. PubMed ID: 38824202
[TBL] [Abstract][Full Text] [Related]
40. A comprehensive bioinformatic analysis of cyclin-dependent kinase 2 (CDK2) in glioma.
Liu H; Weng J
Gene; 2022 May; 822():146325. PubMed ID: 35183683
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
